Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 16 September 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 9 August 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.6 billion in the period from 9 August 2019 to 30 October 2019.
Since the announcement as of 9 September 2019, the following transactions have been made:
|Accumulated, last announcement||2,674,000||935,361,972|
|9 September 2019||130,000||349.77||45,470,371|
|10 September 2019||135,000||333.54||45,027,236|
|11 September 2019||130,000||337.05||43,815,947|
|12 September 2019||130,000||342.32||44,501,640|
|13 September 2019||125,000||335.93||41,991,592|
|Accumulated under the programme||3,324,000||1,156,168,758|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 33,884,044 B shares of DKK 0.20, corresponding to 1.4% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 13 September 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 26,725,012 B shares at an average share price of DKK 328.95 per B share equal to a transaction value of DKK 8,791,122,213.
|Anne Margrethe Hauge||+45 4442 firstname.lastname@example.org|
|Ken Inchausti (US)||+1 609 240 email@example.com|
|Peter Hugreffe Ankersen||+45 3075 firstname.lastname@example.org|
|Valdemar Borum Svarrer||+45 3079 email@example.com|
|Ann Søndermølle Rendbæk||+45 3075 firstname.lastname@example.org|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com|
Company announcement 53 / 2019
Upcoming Life Sciences Events
- December 2019
- Marseille: BioFIT
- London: Genesis 2019
- London: The Pharma Business Development Course